Group 1 - Halper Sadeh LLC is investigating Ventyx Biosciences, Inc. for potential violations related to its sale to Eli Lilly and Company at $14.00 per share [1] - Sun Country Airlines Holdings, Inc. is being investigated for its sale to Allegiant Travel Company, which involves a transaction of 0.1557 shares of Allegiant common stock and $4.10 in cash for each Sun Country share [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - The proposed sale of Ventyx Biosciences, Inc. to Eli Lilly and Company is under investigation to assess whether the offered price of $14.00 per share adequately reflects the company's value [1]. Group 1: Transaction Details - Shareholders of Ventyx will receive $14.00 in cash for each share they own as part of the proposed transaction [1]. - The law firm Kahn Swick & Foti, LLC is investigating the adequacy of this consideration and the process leading to the proposed sale [1]. Group 2: Legal Rights and Contact Information - Individuals who believe the transaction undervalues Ventyx or wish to discuss their legal rights can contact KSF Managing Partner Lewis S. Kahn for more information [2]. - KSF provides a toll-free number and an online resource for further inquiries regarding the case [2].

Company Overview - Ventyx Biosciences develops oral therapies targeting autoimmune, inflammatory, and neurodegenerative diseases [3] Allegations of Wrongdoing - Edelson Lechtzin LLP is investigating Ventyx for potential violations of federal securities laws due to allegations of misleading business information [1] - On December 2, 2025, Ventyx announced a delay in the Phase 2 trial of VTX2735 for recurrent pericarditis, with topline results now expected in Q1 2026. This delay is attributed to testing a new once-daily formulation and expanding the study into Canada, the EU, and the UK [4] - Following the announcement, Ventyx's stock price dropped by $1.44 per share, or 15.35%, closing at $7.94 per share on the same day [4]

Group 1: Acquisition and Strategic Moves - Eli Lilly announced the acquisition of Ventyx Biosciences for $1.2 billion, with a premium of 62%, to enhance its NLRP3 inhibitor pipeline, expected to complete in the first half of 2026 [1] - Bangyao Biotech appointed Xiang Yu as CEO starting January 1, 2026, who brings 17 years of experience in the pharmaceutical and healthcare sectors, aiming to accelerate the commercialization of CGT pipelines [2] Group 2: Market Performance and Product Approvals - Jingfeng Medical's stock surged over 30% on its first day of trading in Hong Kong, reflecting strong market confidence in its surgical robot technology and global strategy [3] - Luye Pharma's innovative drug Ruoxinlin received acceptance for a new indication application in China, targeting generalized anxiety disorder, with a clinical efficacy rate exceeding 80% [4] - Hansoh Pharmaceutical's Amivantamab was approved for a new indication in combination with chemotherapy for advanced non-small cell lung cancer patients with specific EGFR mutations, reinforcing its position in the EGFR-TKI market [5]

Core Viewpoint - The law firm Brodsky & Smith is investigating potential claims against the Board of Directors of Ventyx Biosciences, Inc. for possible breaches of fiduciary duty related to the sale of the company to Eli Lilly and Company for $14.00 per share, totaling approximately $1.2 billion in equity value [1][2]. Group 1 - The investigation focuses on whether the Ventyx Board failed to conduct a fair process in the sale, particularly regarding the fairness of the deal consideration for shareholders [2]. - The sale price of $14.00 per share represents an aggregate equity value of about $1.2 billion [1]. Group 2 - Brodsky & Smith is a litigation law firm with a strong track record in representing shareholders in securities and class action lawsuits, having recovered millions for clients [3]. - The firm has been appointed as lead counsel in various class actions by numerous courts across the country [3].

Core Viewpoint - Eli Lilly (LLY) has agreed to acquire Ventyx Biosciences (VTYX) in an all-cash transaction to expand its oral small molecule therapy product line targeting chronic inflammatory diseases [1]. Group 1 - Eli Lilly's stock decreased by 0.2% in early trading on Thursday [1]. - The acquisition aims to enhance Eli Lilly's portfolio in the area of chronic inflammation [1].

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the sale of Ventyx Biosciences, Inc. to Eli Lilly and Company at a price of $14.00 per share for Ventyx shareholders [1] Group 1 - The investigation focuses on whether the sale price is fair to Ventyx shareholders [1] - Ventyx shareholders are encouraged to learn about their legal rights and options regarding the sale [1] - Contact information for Halper Sadeh LLC is provided for shareholders seeking more information [1]

Core Viewpoint - Eli Lilly (LLY.US) has agreed to acquire Ventyx Biosciences (VTYX.US) for $14 per share in cash, with a total equity value of approximately $1.2 billion, aiming to expand its immunology business [1][1][1] Group 1: Acquisition Details - The acquisition is expected to be completed in the first half of this year and does not include any financing conditions [1][1] - Bank of America Securities is serving as the exclusive financial advisor to Eli Lilly, while Jefferies is the lead financial advisor for Ventyx [1][1] Group 2: Strategic Rationale - Eli Lilly aims to enhance its immunology portfolio, which is identified as a key growth area for the company [1][1] - The company has successfully attracted investor and patient interest in diabetes and obesity treatments, and is looking to further expand its offerings [1][1] Group 3: Current Product Landscape - Eli Lilly currently markets several drugs for inflammatory diseases, including Taltz, although the key patent for Taltz is set to expire in the coming years [1][1] - The company has previously made significant acquisitions, including a $3.2 billion purchase of Morphic Therapeutics for an experimental drug targeting inflammatory bowel disease and a $2.4 billion acquisition of Dice Therapeutics, which develops oral therapies for psoriasis [1][1]

Core Viewpoint - Ademi LLP is investigating Ventyx for potential breaches of fiduciary duty and other legal violations related to its transaction with Eli Lilly, which involves a cash offer of $14.00 per share, valuing the deal at approximately $1.2 billion [1][2]. Group 1: Transaction Details - Ventyx stockholders will receive $14.00 per share in an all-cash transaction valued at around $1.2 billion [2]. - The transaction agreement includes provisions that significantly limit competing offers for Ventyx, imposing penalties if a competing bid is accepted [3]. Group 2: Board Conduct and Shareholder Rights - The investigation focuses on the conduct of Ventyx's board of directors to determine if they are fulfilling their fiduciary duties to all shareholders [3]. - Ademi LLP specializes in shareholder litigation related to buyouts, mergers, and individual shareholder rights [4].

Core Viewpoint - Eli Lilly and Company has announced a definitive agreement to acquire Ventyx Biosciences for $14.00 per share, totaling approximately $1.2 billion, to enhance its capabilities in treating inflammatory-mediated diseases [1][3][4]. Company Overview - Eli Lilly is a biopharmaceutical company focused on innovative therapies for various health challenges, including diabetes, obesity, Alzheimer's disease, and immune system disorders [8]. - Ventyx Biosciences is a clinical-stage biopharmaceutical company developing oral therapies targeting inflammation-mediated diseases, with a focus on small molecule therapeutics [9]. Acquisition Details - The acquisition price represents a 62% premium over Ventyx's 30-day volume-weighted average trading price as of January 5, 2026 [4]. - The transaction is expected to close in the first half of 2026, pending approval from Ventyx stockholders and regulatory approvals [3][4]. - Entities affiliated with New Science Ventures and Ventyx's directors and officers have signed agreements to support the transaction, representing about 10% of Ventyx's outstanding common stock [5]. Clinical Pipeline - Ventyx's pipeline includes NLRP3 inhibitors aimed at treating chronic inflammation across various disease states, including cardiometabolic disorders and neurodegenerative diseases [2][3]. - The company's lead candidates include VTX2735, a Phase 2 NLRP3 inhibitor for recurrent pericarditis, and VTX3232, which has shown promise in reducing cardiovascular risk factors and is also being studied in early-stage Parkinson's disease [9]. Strategic Importance - The acquisition is seen as a strategic move for Lilly to strengthen its portfolio in addressing chronic inflammation, which is increasingly recognized as a key driver of many chronic diseases [3][4]. - Lilly's commitment to advancing innovative oral drugs aligns with Ventyx's focus on unmet medical needs in inflammatory diseases [3].